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Even with an optimal treatment protocol, the median survival of glioblastoma (GB) patients
is only 12–15 months. Hence, there is need for novel effective therapies that improve sur-
vival outcomes. Recent evidence suggests an important role for connexin (Cx) proteins
(especially Cx43) in the microenvironment of malignant glioma. Cx43-mediated gap junc-
tional communication has been observed between tumor cells, between astrocytes and
between tumor cells and astrocytes. Therefore, gap junction directed therapy using a phar-
macological suppressor or modulator, such as tonabersat, could be a promising target in the
treatment of GB. In this preclinical study, we evaluated the possible therapeutic potential of
tonabersat in the F98 model.
Procedures
Female Fischer rats were inoculated with ± 25.000 F98 tumor cells in the right frontal lobe.
Eight days post-inoculation contrast-enhanced T1-weighted (CE-T1w) magnetic resonance
(MR) images were acquired to confirm tumor growth in the brain. After tumor confirmation,
rats were randomized into a Control Group, a Connexin Modulation Group (CM), a Standard
Medical Treatment Group (ST), and a Standard Medical Treatment with adjuvant Connexin
Modulation Group (STCM). To evaluate therapy response, T2-weighted (T2w) and CE-T1w
sequences were acquired at several time points. Tumor volume analysis was performed on
CE-T1w images and statistical analysis was performed using a linear mixed model.
Results
Significant differences in estimated geometric mean tumor volumes were found between
the ST Group and the Control Group and also between the STCM Group and the Control
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Group. In addition, significant differences in estimated geometric mean tumor volumes
between the ST Group and the STCM Group were demonstrated. No significant differences
in estimated geometric mean tumor volumes were found between the Control Group and
the CM Group.
Conclusion
Our results demonstrate a therapeutic potential of tonabersat for the treatment of GB when
used in combination with radiotherapy and temozolomide chemotherapy.
Introduction
Gliomas form a heterogeneous group of tumors of the central nervous system (CNS) and are
categorized into 4 histological grades based on increasing degrees of undifferentation, anapla-
sia and aggressiveness as described by the World Health Organisation (WHO) classification
system [1]. Recently, an updated WHO classification system was released, including histologi-
cal criteria and molecular biomarkers [2]. Malignant gliomas are by far the most common
form of glioma and glioblastoma (GB) accounts for 82% of cases of malignant glioma [3].
Therefore, GB is the most common and malignant glial tumor of the CNS with a global inci-
dence which ranges from 0.59 to 3.69 per 100 000 depending on the reporting country/organi-
zation [4]. Up to now, Magnetic Resonance Imaging (MRI) is the gold standard for the clinical
evaluation of GB and is well suited for longitudinal follow-up. Gadolinium (Gd)-based con-
trast-enhanced (CE) MRI is widely considered as the most accurate imaging tool for diagnosis
of malignant glioma [3,5]. Standard medical treatment of GB consists of maximal surgical
resection followed by radiotherapy (RT) and concomitant chemotherapy with temozolomide
(TMZ) [6]. Unfortunately, despite this multimodal treatment method, standard medical treat-
ment has limited efficacy due to high rates of recurrence, overall resistance to therapy, and
neurological deterioration [7]. Therefore, GB is associated with poor prognosis as the median
patient survival is 12.1–14.6 months from diagnosis, and only 3–5% of the patients survive for
three years or longer [6]. Hence, there is an urgent need for novel effective therapies that act
on GB and improve survival outcomes.
Recent evidence suggests an important role for transmembrane connexin (Cx) proteins in
the microenvironment of malignant glioma [8]. Cxs are proteins that form hemichannels
(HCs) when six of the same Cxs are grouped [9]. The docking of two HCs, belonging to the
membrane of neighboring cells, results in the formation of gap junctional channels (GJs), i.e.,
intercellular channels that allow the direct exchange of ions and low molecular weight mole-
cules (<1.5kDa) between the cytoplasm of neighboring cells [9]. GB cells can interconnect via
microtube-associated gap junctions (tumor microtubes: TMs) based on Cx43. These TMs
allow gap junction-mediated communication (GJC) between tumor cells [10]. Cx43 is sug-
gested to be a driver of tumor invasion, a marker of tumor progression and an inducer of
TMZ resistance in GB cells [8]. TMs also play an important role in potential resistance against
radiotherapeutic damage. Radiotherapy causes increases of intracellular calcium levels, which
are necessary for radiotherapy-induced cytotoxicity. Intercellular TMs can distribute these
critical levels of calcium within the larger cellular network causing nonlethal calcium levels
[10]. Moreover, GJC has also been described between glioma cells and astrocytes and is critical
for several physiological processes. Astrocytes are the most dominant cell type in the brain and
maintain homeostasis of the brain microenvironment [11]. In normal physiological
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conditions, the network of astrocytes has a protective role in the CNS but, under pathological
conditions, astrocytes become activated to protect neurons from injury-induced apoptosis via
GJC [11]. Therefore, gap junction directed therapy using a pharmacological suppressor or
modulator of gap junction activity such as tonabersat could be a promising target in the treat-
ment of GB. Tonabersat is a benzopyran derivate that binds to a unique stereoselective binding
site in astrocytes and inhibits gap junction mediated processes [12]. Moreover, it has been
shown that tonabersat directly reduces opening of HCs under pathological conditions [13].
Tonabersat was also thought to inhibit cortical spreading depression, which is a key mecha-
nism underlying the depolarizing brain waves in migraine with aura. Based on preclinical
results, tonabersat was selected for phase II clinical trials as a prophylactic treatment for
migraine, and it was shown to have a preventive effect on attacks of migraine with aura [14].
Currently, several brain tumor models are used for GB research. We selected the F98 GB
model as it displays all the necessary histological characteristics, is non-immunogenic and less
expensive compared to patient-derived GB models necessitating the use of nude rats [15].
In this preclinical study, we evaluated the possible adjuvant therapeutic effect of tonabersat
in the F98 GB rat model.
Materials and methods
Cell culture
The F98 cell line (ATCC1 CRL-2397™) was generated from Fischer rats after treatment with
N-ethyl-N-nitrosourea and has previously been described in detail [16]. F98 GB cancer cells
were maintained in Dulbecco’s modified Eagle’s medium (DMEM) supplemented with 10%
fetal calf serum (FCS), 1% penicillin-streptomycin antibiotics, 0.0005% fungizone and 1%
pyruvate at 37˚C and 10% CO2.
F98 GB rat model
This study protocol was approved by the Ghent University ethics committee for animal experi-
ments (ECD 17/70). All animals were kept and handled according to the European guidelines
(directive 2010/63/EU) and housed under environmentally controlled conditions (12h normal
light/dark cycles, 20˚C– 24˚C and 40–70% relative humidity, daily monitoring) with food and
water ad libitum.
The F98 GB rat model has previously been described by Bolcaen et al. [17]. Female Fischer
rats (F344/IsoCrl, Charles River1, body weight 174 ± 10 g, mean ± SD) were anesthetized
with an intraperitoneal (IP) injection of a mixture of 74 mg/kg ketamine and 11 mg/kg xyla-
zine and immobilized using a stereotactic frame (Model 902 Dual Small Animal Stereotaxic
frame, Kopf1). Subsequently, the rat head was shaved, swabbed with chlorhexidine and a lon-
gitudinal scalp incision of 10 mm was made. Next, a hole of 1 mm was made through the skull
in the right frontal hemisphere (2 mm posterior and 2.5 mm lateral to bregma) with the use of
a diamond drill (Dremel1). Then, a stereotactically guided syringe, secured into a holder,
containing a 5 μl cell suspension of 25 000 F98 cancer cells was slowly inserted at a depth of 3
mm and the cell suspension was injected over a 2-min period using a microsyringe pumpcon-
troller (Micro 4TM, World Precision Instruments, Sarasota, USA). The syringe was withdrawn
5 minutes post inoculation (PI) and the incision was closed with bone wax (Aesculap AG1)
and sutured.
Taking the humane endpoints into account, animals were immediately euthanized when
clinical or behavioral signs such as balance problems, deterioration, weakness, reduced activ-
ity, absence of grooming or weight loss (> 20%) were observed. Moreover, tumor growth was
monitored by brain MRI (euthanasia when tumor volume > 40% of total brain volume). An
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overview of day and cause of euthanasia for all rats can be found in the supporting information
(S1 Table). All animals were euthanized based on the humane endpoints.
MRI for confirmation of GB growth
Eight days PI, MRI was performed on a 7T system (PharmaScan 70/16, Bruker, Ettlingen, Ger-
many) to confirm GB growth in the rat brain. Rats were anesthetized using isoflurane mixed
with oxygen administered at a flow rate of 0.2 l/min (induction 5%, maintenance 1.5%). Then,
a Gd-based contrast agent (2 mmol/kg, Dotarem, Guerbet) was intravenously (IV) injected
into a tail vein followed by fixation of the rat through the nose cone on the restrainer. A heat-
ing pad was placed beneath each rat to maintain body temperature at 37˚C before they were
placed inside the magnet. A rat brain surface coil (Rapid Biomedical, Rimpar1, Germany)
was applied around the head followed by positioning of the bed in a 72 mm whole body trans-
mitter coil (Rapid Biomedical, Rimpar1, Germany). T2-weighted (T2w) sequences (SE Tur-
boRARE, 109 μm in-plane resolution, TR/TE 3661/37.1 ms, 4 averages, TA 9’45") were
performed to localize the tumor and to assess tumor growth. Contrast-enhanced T1-weighted
(CE-T1w) sequences (SE RARE, 117 μm in-plane resolution, TR/TE 1539/9.7 ms, 3 averages,
TA 4’15”) were acquired to demonstrate the increased permeability of the blood brain barrier
(BBB) present in GB and to measure tumor volumes.
Treatment groups
When the diameter of the tumor was approximately 2–3 mm on the CE-T1w MR image, the
rats were randomized into a Control Group (n = 10), a Standard Medical Treatment Group
(ST, n = 6), a Connexin Modulation Group (CM, n = 5), a Standard Medical Treatment and
Connexin Modulation Group (STCM, n = 8) (Fig 1).
Control Group
The rats in the Control Group received daily IP injections of saline with 20% dimethylsulfoxide
(DMSO, Sigma-Aldrich). These injections were performed to take into account a possible
Fig 1. Overview of the protocol per group.
https://doi.org/10.1371/journal.pone.0224130.g001
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influence of DMSO that was used to dissolve TMZ and tonabersat. The control injections were
performed until the humane endpoints were reached.
CM Group
Therapy with tonabersat as a single agent (10 mg/kg; MedChem Express) was performed
through daily IP injections starting at tumor confirmation until humane endpoints were
reached. Tonabersat was dissolved in 10% DMSO and diluted with phosphate-buffered saline
(PBS) to max 1 ml.
ST Group
The rats in the ST Group received MR-based RT with concomitant chemotherapy with TMZ
(IP injections for 5 days; 29 mg/kg).
MR-based RT. Radiotherapy treatment was performed using MRI-guided conformal arc
treatment with the Small Animal Radiation Research Platform (SARRP, XStrahl, UK). After
IV injection of a Gd-based contrast agent, the rat was fixed on a multimodality bed. Two water
filled capillaries were placed on the rat head and were used as markers to facilitate co-registra-
tion of the CT scan and the MRI scan. CE-T1w sequences were run and the rat was, fixed on
the multimodality bed, transported to the four-axis robotic positioning stage of the SARRP.
First, a treatment planning CT (360 projection acquired over 360 degrees using a 1 mm alu-
minium filter, 1 min acquisition) with 600 μA tube current and 50 kV tube voltage was per-
formed. Then, the CT data were reconstructed using an isotropic voxel size of 0.2 mm and
imported in the treatment planning software (Muriplan, Version 2.0.6, Xstrahl1, UK) to dis-
tinguish air, soft tissue and bone by manual segmentation based on the grey-value histogram.
Co-registration with the MRI was manually done using the capillary markers and the skull.
Based on the CE-T1w MR scan the isocenter of the radiation bundle was set in the middle of
the tumor region. A single dose of 20 Gy was delivered by applying three non-coplanar arc
beams (120˚) using a 5 x 5 mm collimator to include minor position changes of the rat head
during performance of the treatment (voltage X-ray source: 220kV, tube current: 13 mA and
copper filter of 0.15 mm) [18].
Chemotherapy with temozolomide. TMZ (29 mg/kg; MedChem Express) was dissolved in
20% DMSO and diluted with saline to max 1 ml. IP injections of TMZ were performed for 5
consecutive days starting at the day of RT.
STCM Group
In addition to the standard medical treatment, rats from the STCM received connexin modu-
lation with tonabersat (10 mg/kg; MedChem Express). Tonabersat was dissolved in 10%
DMSO and diluted with phosphate-buffered saline (PBS) to max 1 ml. Tonabersat were
administered through daily IP injections, starting from tumor confirmation (i.e. one day
before RT and chemotherapy with TMZ) until humane endpoints were reached. To avoid a
possible interaction between IP injection of tonabersat and IP injection of TMZ, the injections
were given with minimum 8 hours difference, which was an arbitrary choice.
MRI for follow-up of GB growth
To evaluate therapy response, T2w and CE-T1w MRI sequences were run at day 3, 6, 10, 13,
then every two days until day 39 (day 1 = start of standard medical treatment or first control
injection).
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Image analysis
Tumor volumes were measured on CE-T1w MR images by manually outlining the hyperin-
tense regions on individual slices using OsiriX software (OsiriX v.5.8.1). The obtained tumor
areas were then multiplied by the slice thickness (0.6 mm) to calculate GB volume.
Statistical analysis
Traditional ANOVA and regression models assume that individual observations are uncorre-
lated. In the present study, rats were randomized into treatment groups and multiple tumor
volume measurements per rat were performed at several time points. Rats were euthanized at
different time points based on their clinical symptoms resulting in missing data that meet the
missing-at-random principle (i.e., missing data are dependent on therapy and pretreatment
tumor volume, but independent on unobserved variables). Moreover, the clustered structure
of the data (i.e., several series of rats were inoculated with cancer cells) required a multilevel
approach. Mixed model analysis provides a general, flexible approach in these situations and is
therefore the most suitable statistical model.
A linear mixed model was fitted for the natural logarithm of tumor volume, with treatment
group, time since tumor confirmation (in days, categorical), their two-way interaction (treat-
ment group � time categorical) and the natural logarithm of pretreatment tumor volume (in
mm3, continuous) in the fixed part of the model, and with a random intercept for series and a
first order autoregressive correlation structure for repeated measurements within the same
animal. Results were backtransformed by taking the exponential of the regression coefficients.
The exponentiated regression coefficients correspond to changes in the ratio of the expected
geometric mean tumor volume.
Results were visualized in a mean profile plot showing the estimated geometric mean
tumor volume according to the treatment group they belong to, and as a function of time since
tumor confirmation in days. Estimates are derived from a model adjusted for pretreatment
tumor volume and correspond to the geometric mean tumor volume when the pretreatment
volume is 17.7 mm3 (17.7 mm3 is the geometric mean tumor volume at tumor confirmation
and is a criterion for the central tendency). A similar model was fitted on all data available of
the first two weeks since tumor confirmation, with time since tumor confirmation (in days) as
a continuous covariate instead of categorical, to estimate the percentage increase in the
expected geometric mean tumor volume per day during the first two weeks for the different
treatment groups. The slopes were compared with those of the control group.
Unadjusted p-values for two-sided tests and 95% confidence intervals are reported. How-
ever, when applying Bonferroni correction, p-values should be compared to a significance
level of 0.13% because in total 38 comparisons were made. Analyses were performed in SPSS,
version 25. Figures were made in R, version 3.5.2.
Histological analysis
When humane endpoints were reached, animals were euthanized by an IV injection of pento-
barbital (120 mg/kg). For a selection of animals the brains were isolated, immersed for 24
hours in 4% paraformaldehyde and embedded in paraffin. Then, the cerebrum was partly sec-
tioned in 5μm slices and stained with Hematoxylin and Eosin (H&E) for histological confirma-
tion of GB development.
Immunohistochemical staining for Ki67, Cx43 or Glial Fibrillary Acidic Protein (GFAP)
were performed on formalin-fixed, paraffin-embedded slices to evaluate GB proliferation,
Cx43 expression and reactive astrocytes, respectively. Sections were incubated for 30 min with
normal swine serum (Ki67 and Cx43) or normal rabbit serum (GFAP), followed by incubation
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with the primary antibodies: rabbit monoclonal (Ki67: 1/50, 2h, Invitrogen MA5-14520);
Cx43: 1/2000, 2h, Abcam ab11370) or mouse monoclonal (GFAP, 1/400, overnight, Thermo-
Fisher, MA5-12023). Then, sections were incubated with biotinylated secondary antibodies (1/
200, 30 min), streptavidin-peroxidase complex (1/200, 30 min) and 3,30- diaminobenzidine
(DAB) peroxidase solution (10 min). Finally, sections were counterstained with haematoxylin
(Mayer) and coverslipped using mounting medium (4111, Richard-Allan Scientific, Thermo
Fisher Scientific) and glass coverslips (24 × 50 mm #1 (631–0146, VWR)).
All sections were digitally scanned at high resolution (40× magnification) with a virtual
scanning microscope (Olympus BX51, Olympus Belgium SA/NV, Berchem, Belgium).
Results
Follow-up of GB growth: Mean profile plot
T2w and CE-T1w MR images were acquired for follow-up of GB growth. Eight days after inoc-
ulation of F98 cancer cells, the first hyperintensities due to GB growth were visible on T2w and
CE-T1w images. CE-T1w images were used for analysis of GB volumes. Fig 2 and Table 1
show the estimated geometric mean tumor volumes according to treatment group as a func-
tion of time since tumor confirmation in days for animals with a pretreatment tumor volume
of 17.7 mm3 (i.e., the geometric mean pretreatment tumor volume). The measured tumor vol-
umes can be found in the supporting information (S2 Table).
Fig 2. Graphical visualization of tumor growth per treatment group. Estimated geometric mean tumor volumes according to treatment group as a function
of time since tumor confirmation in days for animals with a geometric mean pretreatment tumor volume of 17.7 mm3.
https://doi.org/10.1371/journal.pone.0224130.g002
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GB in the Control Group showed rapid proliferation encompassing almost the entire right
cerebral hemisphere at day 13 to 15, leading to euthanasia of all rats (Fig 3A). At day 13, the
estimated geometric mean tumor volume for rats in the Control Group, with a pretreatment
tumor volume of 17.7 mm3, was 344.6 mm3 (95% CI from 223.7 mm3 to 530.9 mm3). At day
15, the estimated geometric mean tumor volume for rats in the Control Group, with a pretreat-
ment tumor volume of 17.7 mm3, was 462.2 mm3 (95% CI from 291.5 mm3 to 733.1mm3)
(Table 1).
A similar trend of rapid GB growth was observed in the CM Group. At day 15 to 17, nearly
the entire right cerebral hemisphere was covered by GB leading to euthanasia of all animals
(Fig 3B). At day 15, the estimated geometric mean tumor volume for rats in the CM Group,
with a pretreatment tumor volume of 17.7 mm3, was 345.2 mm3 (95% CI from 156.2 mm3 to
762.9 mm3). At day 17, the estimated geometric mean tumor volume for rats in the CM Group
with a pretreatment tumor volume of 17.7 mm3, was 359.8 mm3 (95% CI from 154.7 mm3 to
836.6 mm3) (Table 1).
GB growth was a slower process in the ST Group and the STCM Group (Fig 3C and 3D).
For the ST Group, estimated geometric mean tumor volumes comparable with the end-point
estimated geometric mean tumor volumes of the Control Group and the CM Group were
reached at day 29 and day 31. At day 29, the estimated geometric mean tumor volume for rats
in the ST Group with a pretreatment tumor volume of 17.7 mm3, was 398.5 mm3 (95% CI
from 236.5 mm3 to 671.5 mm3). At day 31, the estimated geometric mean tumor volume for
rats in the ST Group with a pretreatment tumor volume of 17.7 mm3, was 485.7 mm3 (95% CI
from 284.6 mm3 to 829 mm3) (Table 1). For rats in the STCM Group with a pretreatment
Table 1. Overview of estimated geometric mean tumor volumes.
Time since Tumor Confirmation
(in days)




Standard Medical Treatment and Connexin
Modulation Group
3 43.8 (28.7–66.8) 52.7 (25.6–108.3) 50.3 (32.2–78.6) 38.1 (25.1–57.6)
6 84.5 (55.4–129) 99.3 (48.3–204) 46.4 (29.7–72.6) 37.7 (24.9–57.1)
10 177.7 (115.9–
272.3)
176.4 (85.8–362.5) 49 (31.4–76.7) 30.4 (20.1–46.1)
13 344.6 (223.7–
530.9)
230.5 (110.7–479.7) 59.6 (38.1–93.2) 29.1 (19.1–44.3)
15 462.2 (291.5–
733.1)
345.2 (156.2–762.9) 67.4 (43.1–105.4) 27.6 (18.1–42)
17 359.8 (154.7–836.6) 80.5 (51.5–125.9) 26.1 (17.1–39.9)
19 114.6 (73.3–179.2) 27.1 (17.7–41.4)
21 140.1 (88.9–220.8) 28.5 (18.6–43.8)
23 182.1 (113.9–291.3) 33.7 (21.9–51.8)
25 222 (137.2–359.1) 38.9 (25–60.5)
27 285.8 (172.6–473.2) 52.1 (33.2–81.7)
29 398.5 (236.5–671.5) 74.2 (46.9–117.4)
31 485.7 (284.6–829) 101.2 (63–162.5)
33 603.5 (340.7–1068.7) 135.5 (83.4–220.2)
35 864.9 (439.8–1700.8) 173.4 (105.8–284.4)
37 1149 (544.3–2425.6) 229.5 (137–384.3)
39 1333.2 (600.7–2959)
Estimated geometric mean tumor volumes according to treatment for several time points since tumor confirmation for animals with a geometric mean pretreatment
tumor volume of 17.7 mm3.
https://doi.org/10.1371/journal.pone.0224130.t001
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tumor volume of 17.7 mm3, the maximum estimated mean tumor volume reached was only
229.5 mm3 (95% CI from 137 mm3 to 384.3 mm3) at day 37 (Table 1).
Evaluation of treatment efficiency via GB volume measurement
Treatment efficiency was evaluated by pairwise comparison of estimated geometric mean
tumor volumes at certain time points, assuming they had the same pretreatment tumor vol-
ume (Table 2).
At day 3 and 6, no significant differences in estimated geometric mean tumor volumes were
observed between the ST Group and the Control Group (p = 0.5929 and p = 0.0263, respec-
tively), between the STCM Group and the Control Group (p = 0.5643 and p = 0.0022, respec-
tively) and between the CM Group and the Control Group (p = 0.6069 and p = 0.6548,
respectively).
At day 10, 13 and 15, significant differences in estimated geometric mean tumor volumes
were found between the ST Group and the Control Group, indicating that standard medical
treatment with radiotherapy and TMZ chemotherapy significantly reduced GB growth from
day 10 since tumor confirmation (all p-value < 0.0001). Standard medical treatment supple-
mented with tonabersat also showed significant differences in estimated geometric mean
tumor volumes at day 10, 13 and 15 compared to the Control Group (all p-value < 0.0001). In
contrast, no significant differences in estimated geometric mean tumor volumes were found
between the Control Group and the CM Group at any time point, indicating that tonabersat as
a single agent did not significantly reduce GB proliferation.
Fig 3. MR imaging of GB growth per treatment group. In vivo serial CE-T1w MRI scans in the same rat showing GB growth in the four treatment
groups.
https://doi.org/10.1371/journal.pone.0224130.g003
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Pairwise comparisons of estimated geometric mean tumor volumes were also performed
between the ST Group and the STCM Group to evaluate the possible adjuvant effect of tona-
bersat on standard medical treatment of GB. Statistical analysis showed significant differences
in estimated geometric mean tumor volumes between the ST Group and the STCM Group
from day 15 onwards (p-value at day 15 = 0.0006, p-values at day 17, 19, 21, 23, 25, 27, 29, 31
and 33 < 0.0001, p-value at day 35 = 0.0001 and p-value at day 37 = 0.0002).
The estimated difference between the estimated geometric mean tumor volume of the ST
Group and the STCM Group, assuming that the rats had the same pretreatment tumor vol-
ume, was also calculated (Table 2). At day 15, the estimated geometric mean tumor volume of
the STCM Group was 0.41 times the estimated geometric mean tumor volume of the ST
Group, meaning the estimated geometric mean tumor volume decreases with 59% in the
Table 2. Comparison of estimated mean tumor volumes between treatment groups.
Group Reference group Time (days) Estimated % diff LCL UCL P
Standard Medical Treatment Group Control Group 3 1.15 0.68 1.94 0.5929
Standard Medical Treatment and Connexin Modulation Group Control Group 3 0.87 0.53 1.42 0.5643
Standard Medical Treatment and Connexin Modulation Group Standard Medical Treatment Group 3 0.76 0.47 1.22 0.2479
Connexin Modulation Group Control Group 3 1.2 0.52 2.76 0.6069
Standard Medical Treatment Group Control Group 6 0.55 0.33 0.93 0.0263
Standard Medical Treatment and Connexin Modulation Group Control Group 6 0.45 0.27 0.73 0.0022
Standard Medical Treatment and Connexin Modulation Group Standard Medical Treatment Group 6 0.81 0.5 1.31 0.387
Connexin Modulation Group Control Group 6 1.17 0.51 2.7 0.6548
Standard Medical Treatment Group Control Group 10 0.28 0.16 0.47 < 0.0001
Standard Medical Treatment and Connexin Modulation Group Control Group 10 0.17 0.1 0.28 < 0.0001
Standard Medical Treatment and Connexin Modulation Group Standard Medical Treatment Group 10 0.62 0.38 1 0.0516
Connexin Modulation Group Control Group 10 0.99 0.43 2.28 0.9832
Standard Medical Treatment Group Control Group 13 0.17 0.1 0.3 < 0.0001
Standard Medical Treatment and Connexin Modulation Group Control Group 13 0.08 0.05 0.14 < 0.0001
Standard Medical Treatment and Connexin Modulation Group Standard Medical Treatment Group 13 0.49 0.3 0.79 0.0047
Connexin Modulation Group Control Group 13 0.67 0.29 1.56 0.3069
Standard Medical Treatment Group Control Group 15 0.15 0.08 0.26 < 0.0001
Standard Medical Treatment and Connexin Modulation Group Control Group 15 0.06 0.03 0.1 < 0.0001
Standard Medical Treatment and Connexin Modulation Group Standard Medical Treatment Group 15 0.41 0.25 0.66 0.0006
Connexin Modulation Group Control Group 15 0.75 0.3 1.86 0.5049
Standard Medical Treatment and Connexin Modulation Group Standard Medical Treatment Group 17 0.32 0.2 0.53 < 0.0001
Standard Medical Treatment and Connexin Modulation Group Standard Medical Treatment Group 19 0.24 0.14 0.39 < 0.0001
Standard Medical Treatment and Connexin Modulation Group Standard Medical Treatment Group 21 0.2 0.12 0.34 < 0.0001
Standard Medical Treatment and Connexin Modulation Group Standard Medical Treatment Group 23 0.18 0.11 0.31 < 0.0001
Standard Medical Treatment and Connexin Modulation Group Standard Medical Treatment Group 25 0.18 0.1 0.3 < 0.0001
Standard Medical Treatment and Connexin Modulation Group Standard Medical Treatment Group 27 0.18 0.1 0.32 < 0.0001
Standard Medical Treatment and Connexin Modulation Group Standard Medical Treatment Group 29 0.19 0.1 0.33 < 0.0001
Standard Medical Treatment and Connexin Modulation Group Standard Medical Treatment Group 31 0.21 0.11 0.38 < 0.0001
Standard Medical Treatment and Connexin Modulation Group Standard Medical Treatment Group 33 0.22 0.12 0.43 < 0.0001
Standard Medical Treatment and Connexin Modulation Group Standard Medical Treatment Group 35 0.2 0.09 0.43 0.0001
Standard Medical Treatment and Connexin Modulation Group Standard Medical Treatment Group 37 0.2 0.09 0.46 0.0002
Pairwise comparison of estimated geometric mean tumor volumes between treatment groups at certain time points, given they had the same pretreatment tumor
volume.
https://doi.org/10.1371/journal.pone.0224130.t002
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STCM Group compared to the ST Group (95% CI for this ratio from 0.25 to 0.66, p = 0.0006).
At day 21, the estimated geometric mean tumor volume of the STCM Group was 0.2 times the
estimated geometric mean tumor volume of the ST Group, indicating that the estimated geo-
metric mean tumor volume of the STCM Group is now only 20% of the estimated geometric
mean tumor volume of the ST Group (95% CI for this ratio from 0.12 to 0.34, p< 0.0001).
From day 21 onwards, the estimated geometric mean tumor volume in the STCM Group was
about 20% of the estimated geometric mean tumor volume ST Group at each time point.
Analysis of daily change in estimated geometric mean tumor volumes
between day 3 and 13: Pairwise comparison of the percentage tumor
growth
The daily change in estimated geometric mean tumor volume between day 3 and 13 was calcu-
lated for all groups (Table 3). For the Control group, the estimated geometric mean tumor vol-
ume increases significantly by 22.7% every day (p< 0.001), while in the ST Group, the
estimated geometric mean tumor volume only increases with 1.7% (p = 0.321). The difference
in daily change between the Control group and the ST Group is highly significant (p< 0.001).
Analysis of the daily change in estimated geometric mean tumor volume in the STCM Group
shows a decrease of 2.7% every day (p = 0.064), which is also significantly different compared
to the daily increase of 22.7% in the Control Group (p < 0.001). These results indicate a slower
proliferation of GB in the ST Group and the STCM Group compared to the Control Group. In
the Connexin Modulation Group, the estimated geometric mean tumor volume increases sig-
nificantly with 16.9% every day (p< 0.001), which is not significantly different compared to
the Control Group (p = 0.054).
Histological analysis
H&E staining performed on paraffin-embedded slices of a resected GB of a rat at the end of
the experiment confirmed GB development in the rat brain (Fig 4A). GB is typically character-
ized by tumor necrosis (region 1), tumor (region 2) with strong infiltration (region 3) in the
surrounding healthy brain tissue (region 4). Ki67 expression indicated that GB was highly pro-
liferative, except for the necrotic tumor core (region 1) (Fig 4B). GFAP-positive reactive astro-
cytes and enhanced Cx43 expression were present at the peritumoral zone with infiltrating
cancer cells, but absent in the necrotic tumor core (Fig 4C and 4D). Cx43 expression is specifi-
cally associated with reactive astrocytes (GFAP).
Discussion
The short median survival and poor prognosis of patients diagnosed with GB implicates a high
need for novel therapeutic approaches. A recent review by Grek et al. highlighted the impor-
tant role of Cx proteins in the microenvironment of malignant glioma [8]. Several studies have
indicated Cx43, the most ubiquitous connexin, as an operator of tumor invasion, an indicator
Table 3. Pairwise comparisons of the percentage tumor growth between day 3 and 13 for all treatment groups.
Group % increase per day LCL UCL P % diff compared to Control LCL UCL P
Control Group 1.227 1.193 1.262 < 0.001
Standard Medical Treatment Group 1.017 0.984 1.051 0.321 0.828 0.793 0.865 < 0.001
Standard Medical Treatment and Connexin Modulation Group 0.973 0.945 1.002 0.064 0.793 0.761 0.825 < 0.001
Connexin Modulation Group 1.169 1.122 1.218 < 0.001 0.952 0.906 1.001 0.054
https://doi.org/10.1371/journal.pone.0224130.t003
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of tumor progression and an inducer of TMZ resistance in GB cells [8,19–24]. Cx43 peptidomi-
metics offer a therapeutic opportunity via mechanisms that are able to modulate gap junctional
activity between tumor cells and cells in the peritumoral zone. Cx43 peptidomimetics can target
Cx43-based GJs and/or hemichannels, as well as proteins that interact with Cx43 at the cyto-
plasmic site. Murphy et al. recently demonstrated that Cx43 is crucial for TMZ resistance and
aCT1 (C-terminal mimetic peptide of Cx43), a selective inhibitor of Cx43 channels, could restore
TMZ sensitivity in TMZ-resistant/Cx43-high GB cells [21]. aCT1 was also capable of inhibiting
the growth of LN229/glioma stem cell tumors in mice treated with TMZ [25]. Moreover, combin-
ing aCT1 with TMZ further strengthened the inhibition of GB stem cell self-renewal and viability
[25]. In addition to aCT1, a number of other Cx43 peptidomimetics including PEP-2, JM2, L2,
Gap 26, Gap 27 and Gap 19 have currently been investigated for their therapeutic potential [8].
An alternative approach targeting gap junctional activity may involve the use of monoclonal
antibodies against the second extracellular fragment of Cx43 (MAbE2Cx43) [26]. The
Fig 4. Histological analysis performed on paraffin-embedded slices of resected GB of a rat. A. H&E staining confirmed the presence of GB characterized by central
tumor necrosis (1), tumor (2) and the peritumoral zone with infiltrating cancer cells (3) surrounded by healthy brain tissue (4). B. Immunohistochemistry for Ki67
indicated that GB is highly proliferative, except for the necrotic tumor core: tumor necrosis (1), tumor (2), peritumoral zone with infiltrating cancer cells (3) and healthy
brain tissue (4). C-D. Immunohistochemistry for GFAP and Cx43 demonstrated GFAP-positive reactive astrocytes and enhanced Cx43 expression at the peritumoral
zone.
https://doi.org/10.1371/journal.pone.0224130.g004
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efficiency of the antibodies was investigated using combinations of TMZ chemotherapy and
fractionated radiotherapy in the C6 glioma rat model [27]. Treatment of GB with MAbE2Cx43
as a single agent showed significant inhibition of tumor growth. A combination of IV injection
of MAbE2Cx43 and radiotherapy was demonstrated to be most effective for inhibition of
tumor growth, possibly because of an increase in BBB permeability after irradiation. Treat-
ment with chemotherapy and MAbE2Cx43 was not successful, probably caused by competitive
inhibition between MAbE2Cx43 and TMZ [27].
Cx43-mediated GJC have been observed between tumor cells, between astrocytes and
between tumor cells and astrocytes [8]. Chen et al. suggested tonabersat, a benzopyran derivate
that binds to a unique stereoselective binding site in astrocytes, as a potential drug to treat
established brain metastasis [12]. Tonabersat is an orally bioavailable gap junction modulator
that inhibits the release of cytokines that protect brain metastatic cells against chemotherapeu-
tic and physiological stress. The therapeutic effect of tonabersat (10 mg/kg per day, starting 14
days after cancer cell inoculation) as a single agent and in combination with carboplatin (5
mg/kg per 5 days, starting 14 days after cancer cell inoculation) has been investigated in mice
using a brain metastatic model derived from mammary adenocarcinomas. Brain metastatic
lesions were quantified based on bioluminescent imaging. Both treatment approaches signifi-
cantly inhibited progression of the brain metastatic lesions [12].
In this preclinical study, we assessed the therapeutic potential of tonabersat in the F98 GB
rat model. For this purpose, the geometric estimated mean tumor volumes were evaluated at
several time points for four treatment groups (Control Group, ST Group, STCM Group and
CM Group). The rats in the Control Group showed rapid GB proliferation, leading to early
euthanasia due to clinical deterioration. GB proliferation was slowed down in the ST Group.
Standard medical treatment with radiotherapy and TMZ chemotherapy significantly inhibited
GB proliferation, confirming the effectiveness of standard medical treatment in the F98 GB rat
model [17]. To assess the therapeutic potential of tonabersat, tonabersat was evaluated as a sin-
gle agent and in combination with standard medical treatment. Our results demonstrated the
efficacy of standard medical treatment supplemented with tonabersat as the geometric esti-
mated mean tumor volumes were significantly lower in the STCM Group compared to the
Control Group on day 10, 13 and 15. To evaluate if standard medical treatment supplemented
with tonabersat was more effective then standard medical treatment, pairwise comparison of
the estimated geometric mean tumor volumes between both groups was performed. Statistical
analysis showed significant differences in estimated geometric mean tumor volumes from day
15 onwards. From day 20 onwards, the geometric mean tumor volume in the STCM Group is
about 80% lower than the estimated geometric mean tumor volume in the ST Group. Our
results indicate the adjuvant therapeutic potential of tonabersat for the treatment of GB when
used in combination with radiotherapy and TMZ chemotherapy. This might reflect that tona-
bersat is active at the infiltrative border of the tumor, which can be confirmed by histological
analysis that showed enhanced Cx43 expression and GFAP-positive reactive astrocytes at the
peritumoral zone of GB, indicative for gliomagenesis, tumor progression and treatment resis-
tance. Treatment of GB with tonabersat as a single agent was not successful as no significant
reduction of GB growth was found. In contrast, Chen et al. demonstrated a significant reduced
progression of brain metastatic lesions in mice when tonabersat was administrated as a single
agent [12]. A possible explanation for this different result can be assigned to the complex and
dual functions of connexins in cancer. Connexins can act as tumor suppressors or enhancers
depending on the stage of carcinogenesis. Moreover, connexins are not only present in tumor
tissue but also in host tissue [8,28–31].
There are however a few shortcomings of our study. No survival analysis was performed
because it is not ethically justified in animal experiments. Moreover, several rats (n = 6) needed
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to be euthanized because of extended extra-cranial and/or extra-axial tumor development (Fig
5). Extra-cranial tumor formation was probably due to backflow of tumor cells through the
injection track leading to proliferation of the cancer cells on the skull. Radiotherapy only tar-
geted intra-cerebral GB, allowing uncontrolled proliferation of the extra-cranial tumor fol-
lowed by invasion through the cranial sutures and thus extra-axial tumor formation. These
extra-axial tumors became large space-occupying lesions necessitating euthanasia. Mainly the
STCM Group developed extra-axial tumor growth, probably due to the extended lifespan as a
result of the effective combination of RT, TMZ chemotherapy and Cx modulation with tona-
bersat. The uncontrolled proliferation of extra-cranial and extra-axial tumors allows us to
assume that the effect of radiotherapy is of utmost importance in treatment of GB. Radiother-
apy can increase the permeability of the blood brain barrier and therefore allow more efficient
delivery of tonabersat to the tumor [32].
Another limitation of this study is related to the administration of radiotherapy using the
SARRP. Rats receive radiotherapy in a single dose of 20 Gy instead of 30 fractions of 2 Gy. It is
however stated that the biological effect of a single dose of 20 Gy should approximately equal
the dose of 30 fractions of 2 Gy used in the clinic [17]. Nevertheless, differences in biological
effect are still possible due to the higher dose.
In summary, our preclinical results using combinations of radiotherapy, chemotherapy and
tonabersat provide a proof of concept for the adjuvant therapeutic potential of tonabersat for
the treatment of GB.
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